Better Therapeutics, Inc. – NASDAQ:BTTX

Add to watchlist

Market closed

Open in about 16 hours

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	5.45K
Enterprise value	30.70M

P/E	-0.46
EV/Sales	N/A
EV/EBITDA	-0.57
Price/Sales	N/A
Price/Book	-35.11
PEG ratio	-0.41
EPS	-1.15

Revenue	N/A
EBITDA	-28.81M
Income	-31.57M
Revenue Q/Q	N/A
Revenue Y/Y	-100%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Better Therapeutics, Inc. (NASDAQ:BTTX): Profit margin
Dec 2022	0	-8.76M
Mar 2023	0	-9.35M
Jun 2023	0	-7.58M
Sep 2023	0	-5.86M

Better Therapeutics Financials Estimate

Q Y

Better Therapeutics, Inc. (NASDAQ:BTTX): Analyst Estimates
Sep 2025	1.20M	-10.39M	-863.26%
Dec 2025	1.43M	-10.39M	-724.8%
Mar 2026	5.04M	-8.46M	-167.93%
Jun 2026	6.58M	-8.08M	-122.86%

Analysts Price target
Financials & Ratios estimates

Better Therapeutics, Inc. (NASDAQ:BTTX): Debt to assets
Dec 2022	22943000	23.84M	103.92%
Mar 2023	12808000	22.64M	176.77%
Jun 2023	11604000	22.39M	192.97%
Sep 2023	10722000	20.65M	192.68%

Better Therapeutics, Inc. (NASDAQ:BTTX): Cash Flow
Dec 2022	-6.33M	-360K	132K
Mar 2023	-8.71M	-521K	-435K
Jun 2023	-5.08M	-503K	5.71M
Sep 2023	-5.94M	66K	6.27M

Better Therapeutics alternative data

Better Therapeutics, Inc. (NASDAQ:BTTX): Employee count
Aug 2023	54
Sep 2023	54
Oct 2023	54
Nov 2023	54
Dec 2023	54
Jan 2024	54
Feb 2024	54
Mar 2024	54
Apr 2024	54
May 2024	54
Jun 2024	54
Jul 2024	54

Better Therapeutics
Hedge Funds Holdings Q1 2023

0.46% -6.15%

of BTTX is owned by hedge funds

7 -10

hedge funds hold BTTX stock

109.38K -1.45M

shares is hold by hedge funds

BTTX hedge funds holdings changes

Better Therapeutics
Insider Trading

Better Therapeutics, Inc. (NASDAQ:BTTX): Insider trades (number of shares)
Period	Buy	Sel
Sep 2022	150000	0
Apr 2023	5818181	0
May 2023	600	0
Jul 2023	2418138	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	27 Jul 2023	PERRY DAVID P director, 10 percent owner, officer: Executi.. director, 10 percent owner, off..	Common Stock	1,233,045	$0.73	$900,123
Purchase	27 Jul 2023	BERMAN MARK A. officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	54,802	$0.73	$40,005
Purchase	27 Jul 2023	ARMANINO ANDREW J. director director	Common Stock	274,010	$0.73	$200,027
Purchase	27 Jul 2023	GRANGER ELDER director director	Common Stock	34,251	$0.73	$25,003
Purchase	27 Jul 2023	KARBE FRANK director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	137,005	$0.73	$100,014
Purchase	27 Jul 2023	PARKER GEOFFREY M. director	Common Stock	685,025	$0.73	$500,068
Purchase	16 May 2023	GRANGER ELDER director director	Common Stock	600	$0.87	$520
Purchase	10 Apr 2023	KARBE FRANK director, officer: See Remarks director, officer: See Remarks	Common Stock	242,424	$0.83	$200,000
Purchase	10 Apr 2023	PARKER GEOFFREY M. director	Common Stock	303,030	$0.83	$250,000
Purchase	10 Apr 2023	ARMANINO ANDREW J. director director	Common Stock	303,030	$0.83	$250,000

BTTX insider trading transactions

Better Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q3 2023 10 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 14 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 30 Mar 2023	Q4 2022 Earnings Call Transcript

BTTX earnings call transcripts

Better Therapeutics
Executives

Insider	Age	Compensation
Mr. Kevin J. Appelbaum (1965) Co-Founder, Chief Executive Officer & Director	60	$468,120
Dr. Mark A. Berman M.D. (1976) Chief Medical Officer	49	$348,330
Ms. Kristin Wynholds (1973) Chief Product Officer	52	$317,150

Better Therapeutics
Latest News

Wednesday, 22 May 2024
08:55	Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.	businesswire.com
Thursday, 14 March 2024
09:38	Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	businesswire.com
Tuesday, 5 March 2024
09:25	Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	businesswire.com
Monday, 4 March 2024
09:25	Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	businesswire.com
Friday, 1 March 2024
09:00	Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Thursday, 22 February 2024
11:56	Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status	Zacks Investment Research
Wednesday, 9 August 2023
22:34	Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 2 August 2023
17:30	Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023	Business Wire
Tuesday, 11 July 2023
08:57	Why Is Better Therapeutics (BTTX) Stock Up 39% Today?	InvestorPlace
Sunday, 14 May 2023
04:13	Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript	Seeking Alpha
Thursday, 6 April 2023
13:42	Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade	Zacks Investment Research
Monday, 14 November 2022
22:27	Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript	Seeking Alpha
Sunday, 14 August 2022
06:34	Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 28 July 2022
11:10	Why Is Better Therapeutics (BTTX) Stock Up 27% Today?	InvestorPlace
Tuesday, 26 July 2022
07:30	Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes	Business Wire
Monday, 27 June 2022
19:45	3 Penny Stocks That Have Huge Catalysts Ahead	InvestorPlace
Tuesday, 31 May 2022
15:01	Short Squeeze Stocks: RDBX, BTTX and 3 Others Experts Think Are Ready to Pop	InvestorPlace
10:44	5 Short Squeeze Candidates To Watch This Week: Redbox Tops List With Huge Numbers, GameStop Rejoins The Leaderboard Ahead Of Earnings	Benzinga
Thursday, 26 May 2022
11:47	5 Top Penny Stocks For Your Watch List In June 2022	PennyStocks
Tuesday, 24 May 2022
19:50	Top 3 Penny Stocks Outperforming the Stock Market in May 2022	PennyStocks
Friday, 13 May 2022
12:29	Better Therapeutics' (BTTX) CEO Kevin Appelbaum on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 12 May 2022
09:36	Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel	Seeking Alpha
Tuesday, 10 May 2022
12:55	2 Falling Knives to Catch	GuruFocus
Monday, 9 May 2022
16:21	Penny Stocks to Buy Right Now? 3 to Watch as the Stock Market Falls	PennyStocks
Sunday, 8 May 2022
11:30	What You Need to Know About Buying Penny Stocks in 2022	PennyStocks
Wednesday, 4 May 2022
11:05	Penny Stocks With Huge Potential According To 4 Wall Street Analysts	PennyStocks
Monday, 2 May 2022
11:30	Why Is Better Therapeutics (BTTX) Stock Up 30% Today?	InvestorPlace
09:30	Best Penny Stocks to Buy Today? 3 to Watch as the Market Drops Again	PennyStocks
Tuesday, 30 November 2021
14:04	Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases	Seeking Alpha
Monday, 1 November 2021
11:48	Better Therapeutics SPAC Merger: 8 Things for BTTX Stock Investors to Know	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of Better Therapeutics stock today?

One share of Better Therapeutics stock can currently be purchased for approximately $0.
When is Better Therapeutics's next earnings date?

Unfortunately, Better Therapeutics's (BTTX) next earnings date is currently unknown.
Does Better Therapeutics pay dividends?

No, Better Therapeutics does not pay dividends.
How much money does Better Therapeutics make?

Better Therapeutics has a market capitalization of 5.45K.
What is Better Therapeutics's stock symbol?

Better Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "BTTX".
What is Better Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Better Therapeutics?

Shares of Better Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Better Therapeutics's key executives?
Better Therapeutics's management team includes the following people:
- Mr. Kevin J. Appelbaum Co-Founder, Chief Executive Officer & Director(age: 60, pay: $468,120)
- Dr. Mark A. Berman M.D. Chief Medical Officer(age: 49, pay: $348,330)
- Ms. Kristin Wynholds Chief Product Officer(age: 52, pay: $317,150)
Is Better Therapeutics founder-led company?

Yes, Better Therapeutics is a company led by its founder Mr. Kevin J. Appelbaum.
How many employees does Better Therapeutics have?

As Jul 2024, Better Therapeutics employs 54 workers.
When Better Therapeutics went public?

Better Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 17 Mar 2021.
What is Better Therapeutics's official website?

The official website for Better Therapeutics is bettertx.com.
Where are Better Therapeutics's headquarters?

Better Therapeutics is headquartered at 548 Market Street, San Francisco, CA.
How can i contact Better Therapeutics?

Better Therapeutics's mailing address is 548 Market Street, San Francisco, CA and company can be reached via phone at +41 58872311.

Better Therapeutics, Inc.

bettertx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

+41 58872311

548 Market Street
San Francisco, CA 94104

CIK: 0001832415
ISIN: US08773T1043
CUSIP: 08773T104